Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12595850 | 0.85 | HRH3 (0.43) | HRH3KCNH2CHRM2SLC6A2ADRA1A | |
| SCHEMBL12595816 | 0.83 | LMNA (0.51) | HRH3KCNH2CHRM2SLC6A2ADRA1A | |
| SCHEMBL12595747 | 0.82 | LMNA (0.50) | HRH3KCNH2CHRM2SLC6A2ADRA1A | |
| SCHEMBL12595833 | 0.82 | LMNA (0.50) | HRH3KCNH2CHRM2SLC6A2ADRA1A | |
| SCHEMBL12595859 | 0.81 | HRH3 (0.41) | HRH3KCNH2CHRM2SLC6A2ADRA1A | |
| SCHEMBL12595865 | 0.81 | RAD52 (0.44) | HRH3KCNH2CHRM2SLC6A2ADRA1A | |
| SCHEMBL12596072 | 0.80 | LMNA (0.46) | HRH3KCNH2CHRM2SLC6A2ADRA1A | |
| SCHEMBL12595767 | 0.79 | LMNA (0.47) | HRH3KCNH2CHRM2SLC6A2ADRA1A | |
| SCHEMBL12595902 | 0.79 | LMNA (0.42) | HRH3KCNH2CHRM2SLC6A2ADRA1A | |
| SCHEMBL12595917 | 0.79 | LMNA (0.42) | HRH3KCNH2CHRM2SLC6A2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212146-B2 | Substituted pyridazinones for the treatment of tumors | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-12-15 | — | — | US | disclosed |
| US-20130281426-A1 | PYRIDAZINONES, THE PREPARATION METHOD AND THE USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 2013-10-24 | — | — | US | disclosed |
| US-8501731-B2 | Derivatives of 6[3-(trifluoromethyl)phenyl]pyridazin-3(2H)-one having antitumor activity | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2013-08-06 | — | — | US | disclosed |
| US-20110112061-A1 | PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112061-A1 | PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF | PDXK, PNPO, HCCS | HRH3 1737/4885KCNH2 2321/4885CHRM2 2114/4885 |
| US-20130281426-A1 | PYRIDAZINONES, THE PREPARATION METHOD AND THE USE THEREOF | CYP3A5, PDXK, HCCS | HRH3 1562/4885KCNH2 2316/4885CHRM2 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.